NCT06072326 - dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Type 1 Diabetes Mellitus With Diabetic Nephropathy

Interventions

DRUG

Dapagliflozin (Forxiga®)

5 mg/day as a tablet

DRUG

SC0062 strength 10mg

20 mg/day, twice daily, capsule

DRUG

SC0062 and dapagliflozin

20 mg/day SC0062 10 mg twice daily as a capsule in combination with 5 mg/day dapagliflozin 5 mg as a tablet

Trial Locations (7)

Regionshospitalet Gødstrup, Herning

Steno Diabetes Center Aarhus, Aarhus

Turku University Hospital, Turku

Steno Diabetes Center Copenhagen, Copenhagen

University of Helsinki, Helsinki

Amsterdam University Academic Center, Amsterdam

University Medical Center Groningen, Groningen